IFOM

Selected Publications Silvia Marsoni

Publication & Metrics

I have published 114 papers in peer-reviewed international journals, including 89 original research papers (27 as first/last/corresponding author), 4 invited reviews (1 as first/last/corresponding author), 3 invited editorials/commentaries (2 as last/corresponding author), 8 conference paper (3 as last/corresponding author), 10 letter (2 as last/corresponding author)
Total Impact Factor (IF, Thomson Reuters 2017 release): 1115.997.
Average IF: 11.99.
Total citations in Scopus (June 2017): 4760.
Total citations first/last/corresponding author: 1218 (25%).
H-index (Scopus, June 2017): 36

Publications

  1. Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzulli A, Trusolino L, Siena S, Marsoni S, Bardelli A.
    Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
    Cancer Cell. 2018 Jul 9;34(1):148-162.e7. doi: 10.1016/j.ccell.2018.06.004. !PubMed PMID: 29990497.

  2. Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L.
    Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
    Ann Oncol. 2018 May 1;29(5):1108-1119. doi: 10.1093/annonc/mdy100. !PubMed PMID: 29659677; PubMed Central PMCID: PMC5961091.

  3. Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, Ciardiello D, Rachiglio AM, Normanno N, Sartore-Bianchi A, Marsoni S, Bardelli A, Siena S, Ciardiello F.
    Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
    ESMO Open. 2018 Jan 10;3(1):e000299. doi: 10.1136/esmoopen-2017-000299. eCollection 2018. PubMed PMID: 29387480; PubMed Central PMCID: PMC5786925.

  4. Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A.
    Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
    Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29. PubMed PMID: 29186113.

  5. Sartore-Bianchi A, Marsoni S, Siena S.
    Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer.
    JAMA Oncol. 2018 Jan 1;4(1):19-20. doi: 10.1001/jamaoncol.2017.3323. PubMed PMID: 29049531.

  6. Siravegna G, Marsoni S, Siena S, Bardelli A.
    Integrating liquid biopsies into the management of cancer.
    Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. doi: 10.1038/nrclinonc.2017.14. Epub 2017 Mar 2. Review. PubMed PMID: 28252003.

  7. Apicella M, Migliore C, Capelôa T, Menegon S, Cargnelutti M, Degiuli M, Sapino A, Sottile A, Sarotto I, Casorzo L, Cassoni P, De Simone M, Comoglio PM, Marsoni S, Corso S, Giordano S.
    Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
    Oncogene. 2017 Mar 2;36(9):1200-1210. doi: 10.1038/onc.2016.283. Epub 2016 Aug 15. PubMed PMID: 27524418.

  8. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S.
    Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420. PubMed PMID: 27108243.

  9. Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M.
    Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
    Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9. PubMed PMID: 26449765.

  10. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE.
    The genomic landscape of response to EGFR blockade in colorectal cancer.
    Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30. PubMed PMID: 26416732; PubMed Central PMCID: PMC4878148.

  11. Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E.
    KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
    Oncotarget. 2015 Oct 20;6(32):34014-22. doi: 10.18632/oncotarget.5607. PubMed PMID: 26416458; PubMed Central PMCID: PMC4741822.

  12. Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC; TAILOR trialists.
    Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
    Ann Oncol. 2015 Oct;26(10):2079-84. doi: 10.1093/annonc/mdv318. Epub 2015 Jul 24. PubMed PMID: 26209642.

  13. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.
    Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
    Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827b. PubMed PMID: 26151329.

  14. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.
    Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
    Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1. Erratum in: Nat Med. 2015 Jul;21(7):doi:10.1038/nm0715-827b. Nat Med. 2015 Jul;21(7):827. PubMed PMID: 26030179; PubMed Central PMCID: PMC4868598.

  15. Garassino MC, Marsoni S.
    A lesson from vorinostat in pleural mesothelioma.
    Lancet Oncol. 2015 Apr;16(4):359-60. doi: 10.1016/S1470-2045(15)70084-7. Epub 2015 Mar 20. PubMed PMID: 25800895.

  16. Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB.
    Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.
    Clin Cancer Res. 2014 Nov 15;20(22):5663-71. doi: 10.1158/1078-0432.CCR-14-0719. Epub 2014 Sep 24. PubMed PMID: 25252757.

  17. Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D.
    Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.
    Ann Oncol. 2014 Jun;25(6):1222-8. doi: 10.1093/annonc/mdu108. Epub 2014 Mar 7. PubMed PMID: 24608201.

  18. Bergmann L, Enzmann H, Broich K, Hebborn A, Marsoni S, Goh L, Smyth JF, Zwierzina H.
    Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?
    Ann Oncol. 2014 Feb;25(2):303-6. doi: 10.1093/annonc/mdt488. Epub 2013 Dec 10. PubMed PMID: 24335759.

  19. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists.
    Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22. PubMed PMID: 23883922.

  20. de Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, Gebbia V, D'Antonio C, Dal Zotto L, Al-Batran SE, Marsoni S, Wolf M.
    A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.
    J Thorac Oncol. 2013 Aug;8(8):1091-4. doi: 10.1097/JTO.0b013e318293d88c. PubMed PMID: 23857399.

  21. Seymour LK, Calvert AH, Lobbezoo MW, Eisenhauer EA, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies.
    Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
    Eur J Cancer. 2013 May;49(8):1808-14. doi: 10.1016/j.ejca.2013.01.014. Epub 2013 Feb 18. PubMed PMID: 23428669.

  22. Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C.
    A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
    Eur J Cancer. 2013 Jan;49(2):290-6. doi: 10.1016/j.ejca.2012.09.009. Epub 2012 Oct 8. Review. PubMed PMID: 23058787.

  23. Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N.
    Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.
    Br J Cancer. 2012 Sep 25;107(7):1025-30. doi: 10.1038/bjc.2012.371. Epub 2012 Aug 21. PubMed PMID: 22910320; PubMed Central PMCID: PMC3461164.

  24. Mandalà M, Grosso F, Vitalini C, Corradino I, Sanfilippo R, Colombini S, Clerici M, Labianca R, De Pascale A, Marsoni S.
    Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.
    Br J Cancer. 2012 Aug 7;107(4):612-6. doi: 10.1038/bjc.2012.325. Epub 2012 Jul 24. PubMed PMID: 22828607; PubMed Central PMCID: PMC3419966.

  25. Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N.
    An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    Int J Gynecol Cancer. 2012 Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a. PubMed PMID: 22635029.

  26. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L.
    A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2. PubMed PMID: 22586653.

  27. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.
    Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Clin Cancer Res. 2012 May 1;18(9):2515-25. doi: 10.1158/1078-0432.CCR-11-2683. Epub 2012 Mar 5. PubMed PMID: 22392911.

  28. Olmos D, A'Hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB.
    Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.
    J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21. PubMed PMID: 22355064.

  29. Olmos D, Ang JE, Gomez-Roca C, Morales-Barrera R, Vulink AJ, Massard C, Kaye S; EDDN.
    Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients.
    Eur J Cancer. 2012 Mar;48(4):594-6. doi: 10.1016/j.ejca.2011.11.004. Epub 2011 Dec 7. PubMed PMID: 22154652.

  30. Mandala M, Clerici M, Corradino I, Vitalini C, Colombini S, Torri V, De Pascale A, Marsoni S.
    Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.
    Ann Oncol. 2012 Jun;23(6):1416-21. doi: 10.1093/annonc/mdr524. Epub 2011 Nov 2. PubMed PMID: 22052988.

  31. Damia G, Broggini M, Marsoni S, Venturini S, Generali D.
    New omics information for clinical trial utility in the primary setting.
    J Natl Cancer Inst Monogr. 2011;2011(43):128-33. doi: 10.1093/jncimonographs/lgr032. PubMed PMID: 22043059.

  32. Garassino MC, Marsoni S, Floriani I.
    Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.
    J Clin Oncol. 2011 Oct 1;29(28):3835-7; author reply 3837-9. doi: 10.1200/JCO.2011.36.7847. Epub 2011 Aug 29. PubMed PMID: 21876080.

  33. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.
    DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added]. PubMed PMID: 21597022; PubMed Central PMCID: PMC3110173.

  34. Gallerani E, Bauer J, Hess D, Boehm S, Droege C, Jeckelmann S, Miani M, Herrmann R, Marsoni S, Sperka S, Sessa C.
    A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
    Acta Oncol. 2011 Oct;50(7):1105-10. doi: 10.3109/0284186X.2010.543697. Epub 2010 Dec 27. PubMed PMID: 21184645.

  35. Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L.
    Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    J Clin Oncol. 2010 Oct 20;28(30):4554-61. doi: 10.1200/JCO.2009.27.5867. Epub 2010 Sep 20. PubMed PMID: 20855840.

  36. Floriani I, Garassino MC, Broggini M, Veronese S, Marsoni S, Marabese M, Farina G, Scanni A.
    Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?
    J Clin Oncol. 2010 Sep 20;28(27):e467; author reply e468. doi: 10.1200/JCO.2010.28.5973. Epub 2010 Jun 28. PubMed PMID: 20585086.

  37. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S.
    Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
    J Clin Oncol. 2010 Jul 10;28(20):3219-26. doi: 10.1200/JCO.2009.27.1825. Epub 2010 May 24. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664. PubMed PMID: 20498393; PubMed Central PMCID: PMC2903323.

  38. Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G.
    Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
    Breast Cancer Res Treat. 2010 Jun;121(2):399-411. doi: 10.1007/s10549-010-0887-y. Epub 2010 Apr 29. PubMed PMID: 20428938.

  39. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J.
    Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
    Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6. PubMed PMID: 20371675.

  40. Frapolli R, Zucchetti M, Sessa C, Marsoni S, Viganò L, Locatelli A, Rulli E, Compagnoni A, Bello E, Pisano C, Carminati P, D'Incalci M.
    Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
    Eur J Cancer. 2010 Feb;46(3):505-16. doi: 10.1016/j.ejca.2009.11.006. Epub 2009 Dec 16. PubMed PMID: 20007015.

  41. Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L.
    Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
    Eur J Cancer. 2009 Aug;45(12):2116-22. doi: 10.1016/j.ejca.2009.04.002. Epub 2009 May 4. PubMed PMID: 19419856.

  42. Marsoni S, Damia G, Camboni G.
    A work in progress: the clinical development of histone deacetylase inhibitors.
    Epigenetics. 2008 May-Jun;3(3):164-71. Epub 2008 May 9. Review. PubMed PMID: 18487953.

  43. : Sessa C, Perotti A, Lladò A, Cresta S, Capri G, Voi M, Marsoni S, Corradino I, Gianni L.
    Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.
    Ann Oncol. 2007 Sep;18(9):1548-53. PubMed PMID: 17761711.

  44. Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D'Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L.
    Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.
    Ann Oncol. 2007 Mar;18(3):561-8. Epub 2006 Dec 5. PubMed PMID: 17150998.

  45. Sessa C, Viganò L, Grasselli G, Trigo J, Marimon I, Lladò A, Locatelli A, Ielmini N, Marsoni S, Gianni L.
    Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.
    Eur J Cancer. 2006 Jan;42(2):171-8. Epub 2006 Jan 6. PubMed PMID: 16406576.

  46. Sessa C, Marsoni S.
    Randomized single-agents trials in recurrent epithelial ovarian cancer.
    Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:247-51. Review. PubMed PMID: 16343240.

  47. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'ó E, Colombo N.
    Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
    J Clin Oncol. 2005 Mar 20;23(9):1867-74. PubMed PMID: 15774779.

  48. : Marsoni S, Damia G.
    Molecular targeting: new therapeutic strategies to improve tumour apoptosis.
    Ann Oncol. 2004;15 Suppl 4:iv229-31. Review. PubMed PMID: 15477312.

  49. Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G; ACOI/GIVIO/GISCAD Investigators.
    Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
    J Natl Cancer Inst. 2004 May 19;96(10):750-8. PubMed PMID: 15150303.

  50. Sessa C, Perotti A, Salvatorelli E, Minotti G, Viganò L, Lladò A, Capri G, Locatelli A, Colombini S, Peccatori F, Voi M, Marsoni S, Gianni L.
    Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
    Eur J Cancer. 2004 Mar;40(4):563-70. PubMed PMID: 14962724.

  51. Lacombe D, Butler-Smith A, Therasse P, Fumoleau P, Burtles S, Calvert H, Marsoni S, Sessa C, Verweij J.
    Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.
    Cancer Invest. 2003;21(1):137-47. Review. PubMed PMID: 12643015.

  52. Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Ponticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S.
    Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.
    Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):78-92. PubMed PMID: 12504039.

  53. Marsoni S; International Multicenter Pooled Analysis of Colon Cancer Trials Investigators.
    Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer.
    International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol. 2001 Feb;28(1 Suppl 1):14-9. PubMed PMID: 11273584.

  54. Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, Zucchetti M, Viganò L, Gatti A, Minoia C, Liati P, Van den Bosch S, Bernareggi A, Camboni G, Marsoni S.
    Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.
    Ann Oncol. 2000 Aug;11(8):977-83. PubMed PMID: 11038034.

  55. Rougier P, Sahmoud T, Nitti D, Curran D, Doci R, De Waele B, Nakajima T, Rauschecker H, Labianca R, Pector JC, Marsoni S, Apolone G, Lasser P, Couvreur ML, Wils J.
    Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research.
    Lancet. 1998 Jun 6;351(9117):1677-81. PubMed PMID: 9734883.

  56. Zaniboni A, Labianca R, Marsoni S, Torri V, Mosconi P, Grilli R, Apolone G, Cifani S, Tinazzi A.
    GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon.
    Cancer. 1998 Jun 1;82(11):2135-44. PubMed PMID: 9610692.

  57. Marsoni S, Torri W.
    Adjuvant chemotherapy for colon cancer: Italian studies.
    Tumori. 1997 Jan-Feb;83(1 Suppl):S45-7. Review. PubMed PMID: 9154068.

  58. Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, Chiari S, Favalli G, Mangili G, Presti M, et al.
    Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.
    Ann Oncol. 1995 Nov;6(9):887-93. PubMed PMID: 8624291.

  59. Pater JL, Zee B, Myles J, Pignon JP, Milan C, Sahmoud T, Torri V, Marsoni S.
    A proposal for a new approach to intergroup cancer trials.
    Eur J Cancer. 1995 Nov;31A(12):1921-3. PubMed PMID: 8562142.

  60. Marsoni S.
    Fluorouracil and folinic acid in colon cancer. IMPACT Investigators.
    Lancet. 1995 Jun 17;345(8964):1582-3. PubMed PMID: 7791476.

  61. Clerici M, Panvini D, Torri V, Colombo F, Luporini G, Tinazzi A, Nicolucci A, Marsoni S.
    Patterns of care and survival in non small cell lung cancer: 15 years' experience in a general hospital.
    Tumori. 1994 Apr 30;80(2):106-12. PubMed PMID: 8016899.

  62. Marsoni S, Clerici M.
    Efficacy, semantic and chemotherapy in advanced NSCLC.
    Ann Oncol. 1994 Apr;5(4):303-4. PubMed PMID: 8075026.

  63. Bertolini G, Apolone G, Liberati A, Marsoni S, Scarpiglione N.
    [Comorbidity and the physician's decision: the case of undertreatment in care of breast tumors].
    Epidemiol Prev. 1994 Mar;18(58):56-64. Italian. PubMed PMID: 8039561.

  64. Alexanian AA, Scorpiglione N, Apolone G, Fossati R, Liberati A, Grilli R, Liberati MC, Marsoni S, Monferroni N, Mosconi P, et al.
    Breast cancer surgery in 30 Italian general hospitals.
    Eur J Surg Oncol. 1993 Apr;19(2):123-9. PubMed PMID: 8491315.

  65. Ghersi D, Parmar MK, Stewart LA, Marsoni S, Williams CJ.
    Early ovarian cancer and the icon trials.
    Eur J Cancer. 1992;28A(6-7):1297. PubMed PMID: 1627401.

  66. Arrigo C, Koier IJ, McVie JG, Marsoni S, Newlands E, Schwartsmann G.
    Minimal guidelines for the monitoring of early clinical trials (phase I-II) in Europe under CRC/EORTC/NCI joint agreement.
    Eur J Cancer. 1992;28A(6-7):1289-92. PubMed PMID: 1627396.

  67. Marsoni S.
    Dilemmas in the development of cytoxic drug analogues.
    Eur J Cancer. 1992;28A(10):1594-5. PubMed PMID: 1389470.

  68. Marsoni S, Torri V, Taiana A, Liberati A, Labianca R, Pancera G, Gray R, Clarke M.
    Efficacy of intraportal infusion for colon cancer: a fair assessment?
    Clin Oncol. 1991 May;9(5):888-9. PubMed PMID: 1958247.

  69. Marsoni S, Valsecchi MG.
    Prognostic factors analysis in clinical oncology: handle with care.
    Ann Oncol. 1991 Apr;2(4):245-7. PubMed PMID: 1868018.

  70. Sessa C, Colombo N, Bolis G, Marsoni S, Mangioni C.
    Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
    Cancer Treat Rev. 1991 Mar;18 Suppl A:37-46. PubMed PMID: 1904308.

  71. Grilli R, Apolone G, Marsoni S, Nicolucci A, Zola P, Liberati A.
    The impact of patient management guidelines on the care of breast, colorectal, and ovarian cancer patients in Italy.
    Med Care. 1991 Jan;29(1):50-63. PubMed PMID: 1986177.

  72. Marsoni S, Torri W, Taiana A, Gambino A, Grilli R, Liati P, Franzosi MG, Pistotti V, Parazzini F, Focarile F, et al.
    Critical review of the quality and development of randomized clinical trials (RCTs) and their influence on the treatment of advanced epithelial ovarian cancer.
    Ann Oncol. 1990 Sep;1(5):343-50. PubMed PMID: 2148106.

  73. Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi U, Bolis G, Bonazzi C, Colombo N, Epis A, Favalli G, et al.
    Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).
    Br J Cancer. 1990 Sep;62(3):444-50. PubMed PMID: 2119684; PubMed Central PMCID: PMC1971438.

  74. Apolone G, Grilli R, Alexanian AA, Confalonieri C, Labianca R, Liati P, Marsoni S, Martignoni G, Mosconi P, Nicoluci A, et al.
    Quality of care of colorectal cancer patients in general hospitals: diffusion and impact of management guidelines.
    Tumori. 1990 Jun 30;76(3):261-9. PubMed PMID: 2368171.

  75. Grilli R, Alexanian AA, Apolone G, Confalonieri C, Fossati R, Liati P, Liberati MC, Marsoni S, Mosconi P, Monferroni N, et al.
    Trends in patterns of care for breast cancer in Italy (1979-1987).
    Tumori. 1990 Apr 30;76(2):184-9. PubMed PMID: 2330611.

  76. Grilli R, Alexanian A, Apolone G, Fossati R, Marsoni S, Nicolucci A, Torri V, Zola P, Compagnucci M, Di Mambro E, et al.
    The impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer.
    Ann Oncol. 1990;1(2):112-8. PubMed PMID: 2078493.

  77. Erba E, Ubezio P, Pepe S, Vaghi M, Marsoni S, Torri W, Mangioni C, Landoni F, D'Incalci M.
    Flow cytometric analysis of DNA content in human ovarian cancers.
    Br J Cancer. 1989 Jul;60(1):45-50. PubMed PMID: 2803914; PubMed Central PMCID: PMC2247358.

  78. Paolucci G, Masera G, Vecchi V, Marsoni S, Pession A, Zurlo MG.
    Treating childhood acute lymphoblastic leukaemia (ALL): summary of ten years' experience in Italy. ALL Steering Committee of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
    Med Pediatr Oncol. 1989;17(2):83-91. PubMed PMID: 2704341.

  79. Bizzi A, Codegoni AM, Landoni F, Marelli G, Marsoni S, Spina AM, Torri W, Mangioni C.
    Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival.
    Cancer Res. 1988 Nov 1;48(21):6222-6. PubMed PMID: 3167868.

  80. : Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE.
    Clinical drug development: an analysis of phase II trials, 1970-1985.
    Cancer Treat Rep. 1987 Jan;71(1):71-80. PubMed PMID: 3791270.

  81. Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R.
    Therapeutic response in phase I trials of antineoplastic agents.
    Cancer Treat Rep. 1986 Sep;70(9):1105-15. PubMed PMID: 3527410.

  82. O'Dwyer PJ, Spiers AS, Marsoni S.
    Association of severe and fatal infections and treatment with pentostatin.
    Cancer Treat Rep. 1986 Sep;70(9):1117-20. PubMed PMID: 3488805.

  83. Foster BJ, Clagett-Carr K, Marsoni S, Simon R, Leyland-Jones B.
    Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
    Cancer Treat Rep. 1986 Aug;70(8):1003-14. Review. PubMed PMID: 3089597.

  84. Weiss RB, Grillo-López AJ, Marsoni S, Posada JG Jr, Hess F, Ross BJ.
    Amsacrine-associated cardiotoxicity: an analysis of 82 cases.
    J Clin Oncol. 1986 Jun;4(6):918-28. PubMed PMID: 3519882.

  85. Grieshaber CK, Marsoni S.
    Relation of preclinical toxicology to findings in early clinical trials.
    Cancer Treat Rep. 1986 Jan;70(1):65-72. PubMed PMID: 3943115.

  86. Wittes RE, Marsoni S, Simon R, Leyland-Jones B.
    The phase II trial.
    Cancer Treat Rep. 1985 Nov;69(11):1235-9. PubMed PMID: 4092188.

  87. Marsoni S, Ungerleider RS, Hurson SB, Simon RM, Hammershaimb LD.
    Tolerance to antineoplastic agents in children and adults.
    Cancer Treat Rep. 1985 Nov;69(11):1263-9. PubMed PMID: 2418966.

  88. Liberati A, Mangioni C, Bratina L, Carinelli G, Marsoni S, Parazzini F, Regallo M, Talamini R, Tognoni G.
    Process and outcome of care for patients with ovarian cancer.
    Br Med J (Clin Res Ed). 1985 Oct 12;291(6501):1007-12. PubMed PMID: 3931767; PubMed Central PMCID: PMC1416949.

  89. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE.
    Etoposide (VP-16-213). Current status of an active anticancer drug.
    N Engl J Med. 1985 Mar 14;312(11):692-700. Review. PubMed PMID: 2983208.

  90. O'Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S.
    Teniposide: a review of 12 years of experience.
    Cancer Treat Rep. 1984 Dec;68(12):1455-66. Review. PubMed PMID: 6391663.

  91. O'Dwyer PJ, Shoemaker DD, Jayaram HN, Johns DG, Cooney DA, Marsoni S, Malspeis L, Plowman J, Davignon JP, Davis RD.
    Tiazofurin: a new antitumor agent.
    Invest New Drugs. 1984;2(1):79-84. Review. PubMed PMID: 6381381.

  92. Marsoni S, Wittes R.
    Clinical development of anticancer agents--a National Cancer Institute perspective.
    Cancer Treat Rep. 1984 Jan;68(1):77-85. PubMed PMID: 6362870.

  93. Shoemaker DD, O'Dwyer PJ, Marsoni S, Plowman J, Davignon JP, Davis RD.
    Spiromustine: a new agent entering clinical trials.
    Invest New Drugs. 1983;1(4):303-8. Review. PubMed PMID: 6381379.

  94. : Morasca L, Marsoni S, Pisoni MB, Piazza E, Vago G, Casali W, Cogo R, Bianchi C, Scapaticci R.
    VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.
    Cancer Chemother Pharmacol. 1982;7(2-3):209-10. PubMed PMID: 7083461.

  95. Macdonald JS, Marsoni S, Bruno S, Poster D.
    Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
    Recent Results Cancer Res. 1982;80:323-30. PubMed PMID: 6977170.

  96. Pisoni MB, Libretti A, Piazza E, Vago G, Scapaticci R, Bianchi C, Tomirotti M, Scanni A, Calzavara MP, Cassani L, Scarpazza G, Marsoni S, Morasca L.
    Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.
    Cancer Treat Rep. 1981 Jul-Aug;65(7-8):731-2. PubMed PMID: 6788372.

  97. Ottolenghi I, Piazza E, Marsoni S, Trabattoni A, Natale N, Recchia M, Morasca L.
    Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate.
    Eur J Cancer. 1981 Mar;17(3):365-6. PubMed PMID: 6167447.

  98. Libretti A, Piazza E, Scanni A, Tomirotti M, Biraghi M, Scapaticci R, Bianchi C, Restelli G, Scarpazza G, Calzavara MP, Marsoni S, Morasca L.
    Bleomycin, vincristine, and methotrexate (BOM) in squamous cell carcinoma of the lung: a phase II study.
    Cancer Treat Rep. 1981 Jan-Feb;65(1-2):171-2. PubMed PMID: 6164485.

  99. Ottolenghi L, Morasca L, Marsoni S, Piazza E, Soresi E, Libretti A, Garattini S.
    Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens.
    Biomedicine. 1980 Oct;32(3):123-7. PubMed PMID: 7448321.

  100. Piazza E, Donelli MG, Broggini M, Sessa C, Natale N, Ottolenghi L, Marsoni S, Libretti A, Mangioni C, Morasca L.
    Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.
    Cancer Treat Rep. 1980 Aug-Sep;64(8-9):845-54. PubMed PMID: 7448822.